EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors

Yumei Cheng iD, Jing Lu, Chonghao Zhang, Weiyuan Yan, Panpan Zhu, Qiuping Qin, Likun Gong

Antibody Therapeutics · 28.03.2025 · 8 (2) · 124-144

DOI: 10.1093/abt/tbaf004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 18.03.2025. Verfasst von Yumei Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pu…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Science and Technology Major Project, Science and Technology Innovation Action Plan of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An antibody–drug conjugate (ADC), consisting of an antibody, a chemical linker, and a payload, can selectively deliver a highly cytotoxic payload to cancer cells and minimize the systemic toxicity of the payload by harnessing the selectivity of the antibody. However, many ADCs have unacceptable toxic effects due to the expression characteristics of target antigens, structural characteristics of antibodies, linker stability and payload properties, which have slowed their development progress. In this review, we describe the effects of the structure of each component of an ADC molecule on its toxicity, explore and discuss the toxicity profiles of various ADCs in the main body tissues/organs by using nonclinical and clinical data obtained from marketed ADCs, aiming to provide a reference for the development of novel ADC molecules and to facilitate related nonclinical and clinical studies.

Schlagwörter

Stichwörter der Autor:innen

ADCclinical studynon-clinical studystructural characteristicstoxicity

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Building A/C, SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District, Zhongshan, Guang…

ORCID-Profile: Yumei Cheng

Förderung

  • National Key Research and Development Program of China
  • Shanghai Municipal Science and Technology Major Project
  • Science and Technology Innovation Action Plan of Shanghai
  • Zhongshan Municipal Bureau of Science and Technology

Zitieren

APA

Cheng, Y., Lu, J., Zhang, C., Yan, W., Zhu, P., Qin, Q., & Gong, L. (2025). Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antibody Therapeutics, 8(2), 124-144. https://doi.org/10.1093/abt/tbaf004

Vancouver

Cheng Y, Lu J, Zhang C, Yan W, Zhu P, Qin Q, et al. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antibody Therapeutics. 2025;8(2):124-144. doi:10.1093/abt/tbaf004

BibTeX
@article{Cheng2025,
  author = {Cheng, Yumei and Lu, Jing and Zhang, Chonghao and Yan, Weiyuan and Zhu, Panpan and Qin, Qiuping and Gong, Likun},
  title = {Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors},
  journal = {Antibody Therapeutics},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {124--144},
  doi = {10.1093/abt/tbaf004}
}
Kostenlos starten →